ArticleFolia microbiologica2025
A rare and first report of Ochrobactrum intermedium co-infection in coxsackievirus-A24-infected acute hemorrhagic conjunctivitis patients.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Epidemic form of acute hemorrhagic conjunctivitis was reported from different geographical locations of the world, during 2023. Since the viral agents are well established behind acute hemorrhagic conjunctivitis outbreaks, this study aims to investigate the bacterial agent associated with the acute hemorrhagic conjunctivitis outbreak that occurred in the eastern Uttar Pradesh region of India. The bacterial infection was investigated in 91 conjunctival swabs collected from acute hemorrhagic conjunctivitis patients during the outbreak. Total nucleic acid was extracted from the ocular swab collected from acute hemorrhagic conjunctivitis patients, followed by the detection of human adenovirus and pan-enterovirus using PCR. Further, the isolation of bacteria was performed using these clinical samples. Characterization of the bacterial isolates was done using the VITEK-2 system and 16S ribosomal RNA sequencing. Of 64 conjunctival swabs positive for coxsackievirus-A24 samples, two clinical specimens showed bacterial growth. Both isolates were identified as Ochrobactrum anthropi via VITEK-2 with 93% and 95% confidence levels. While 16S ribosomal RNA analysis characterized the isolates as Ochrobactrum intermedium. Ochrobactrum intermedium is an emerging multidrug-resistant bacterium and is reported to cause a variety of clinical infections. This study first reported the Ochrobactrum intermedium infection in two coxsackievirus-A24 infected acute hemorrhagic conjunctivitis patients.
Indexed as
Identifiers
40658356What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.